摘要
目的:探究头孢哌酮钠舒巴坦钠联合莫西沙星治疗老年重症肺炎的临床疗效。方法:选取我院诊治的重症肺炎老年患者90例,平均随机分为A、B、C三组。在常规治疗的基础上,A组予以头孢哌酮钠舒巴坦钠治疗,B组予以莫西沙星治疗,C组则予以头孢哌酮钠舒巴坦钠与莫西沙星的联合治疗。分析比较三组患者的临床疗效、细菌清除率、临床症状及体征好转时间、实验室检查指标及不良反应的发生情况。结果:治疗后,C组的临床总有效率、细菌清除率均显著高于A组及B组(P<0.05),B组细菌清除率明显高于A组(P<0.05)。三组患者的WBC、CRP和PaO_2/FiO_2均较治疗前明显改善(P<0.05),而ALT、AST、Scr和BUN均没有显著变化,C组的WBC、CRP、PLT、PaO_2及PaO_2/FiO_2与A组、B组相比差异均有显著性意义(P<0.05)。三组的退热时间、白细胞下降时间、痰液颜色改变时间、肺部炎症明显吸收时间比较有差异(P<0.05),且C组退热时间、白细胞下降时间、痰液颜色改变时间、肺部炎症明显吸收时间均明显短于A组及B组,B组的肺部炎症明显吸收时间短于A组(P<0.05)。三组患者仅出现轻度胃肠道反应、皮疹、失眠等轻微不良反应,不良反应发生率比较差异无统计学意义(P>0.05)。结论:头孢哌酮钠舒巴坦钠联合莫西沙星治疗老年重症肺炎的临床疗效明显优于二者单药治疗,其能显著改善患者的临床症状且安全性高。
Objective： To investigate the clinical efficacy of cefoperazone sodium and sulbactam sodium combined with moxifloxacin in the treatment of elderly patients with severe pneumonia. Methods： 90 senile patients with severe pneumonia were randomly divided into three group A, B and C. On the basis of routine treatment, group A was treated with cefoperazone sodium and sulbactam sodium, group B was treated with moxifloxacin and group C was treated with cefoperazone sodium sulbactam sodium combined with moxifloxacin. The clinical curative effect, bacterial clearance rate, improvement time of clinical symptoms and signs, laboratory examination index and incidence of adverse reaction were analyzed and compared between two groups. Results： After treatment, the total effective rate and the bacterial clearance rate of group C were significantly higher than those of group A and group B, and the bacterial clearance rate of group B was better than that of group A （P 〈0.05）. The levels of WBC, CRP and PaO2/FiO2 in the three groups were significantly improved （P 〈0.05）, while ALT, AST, Scr and BUN showed no changes; the improvement ofWBC, CRP, PLT, PaO2 and PaO2/FiO2 of group C were better than those of group A and group B（P 〈0.05）. The drop time of body temperature, descent time of white blood cell, change time of sputum color, absorption time of lung inflammation were different between three groups and the above indexes of group C were significantly shorter than those of group A and group B, and the absorption time of lung inflammation in group B was shorter than that of group A （P 〈0.05）. Only had mild gastrointestinal reactions, rash, insomnia and other minor adverse reactions were found in the three groups, but no significant difference was found between three groups （P〉0.05）. Conclusion： Cefoperazone sodium and sulbactam sodium combined with moxifloxacin was obviously effective in the treatment of elderly patients with severe pneumonia, which was better than single use of cefoperazone sodium and sulbactam sodium or moxifloxacin, and could significantly improve the clinical symptoms of patients with high safety.
出处
《现代生物医学进展》
CAS
2017年第30期5874-5878,共5页
Progress in Modern Biomedicine
关键词
重症肺炎
老年人
头孢哌酮钠舒巴坦钠
莫西沙星
临床疗效
Severe pneumonia
Senile
Cefoperazone sodium
Sulbactam sodium
Moxifloxacin
Clinical efficacy
